German pharmaceutical company Merck will pour around 53.3 billion won ($49.3 million) over the next two years to build a manufacturing and distribution platform in Asia, including a 10,141-square meter center in Incheon, Korea.

The investment follows the company’s announcement made in November 2016 for a Life Science investment worth 106.5 billion won ($98.6 million) in Nantong, China. The company said it is accelerating single-use manufacturing in China with its Mobius single-use manufacturing to meet growing pharmaceutical demand.

Merck said it would build the Korean manufacturing and distribution center in the Songdo district of Incheon. The center will include infrastructure that will facilitate the supply of Merck products and advanced cell-culture media manufacturing capabilities through its imMEDIAte Advantage® Custom Media, it said.

The plant will be up and running by the end of 2019, according to company expectations.

Along with the Korean center, Merck said it would also build one in Mumbai, India, with plans to begin operation by 2019.

“Our investments in the important Asian markets of Korea, India and China ensure that our customers have ready access to the products needed to develop new therapies and biosimilars that accelerate access to health for people everywhere,” said Udit Batra, Merck executive board’s member and CEO of life science.